Immunohistochemical Expression and Significance of Preferentially Expressed Antigen in Melanoma (PRAME) in Gynecological Tumors: A Single-institution Retrospective Analysis
Anticancer Research · 2024
DOI: 10.21873/anticanres.17377 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2024. Verfasst von Yunjoo Cho und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Antigens, Neoplasm, Immunohistochemistry, Biomarkers, Tumor.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
- Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea hyun-soo.kim@samsung.com.
Zitieren
APA
Cho, Y., & Kim, H. S. (2024). Immunohistochemical Expression and Significance of Preferentially Expressed Antigen in Melanoma (PRAME) in Gynecological Tumors: A Single-institution Retrospective Analysis. Anticancer Research. https://doi.org/10.21873/anticanres.17377
Vancouver
Cho Y, Kim HS. Immunohistochemical Expression and Significance of Preferentially Expressed Antigen in Melanoma (PRAME) in Gynecological Tumors: A Single-institution Retrospective Analysis. Anticancer Research. 2024. doi:10.21873/anticanres.17377
BibTeX
@article{Cho2024,
author = {Cho, Yunjoo and Kim, Hyun-Soo},
title = {Immunohistochemical Expression and Significance of Preferentially Expressed Antigen in Melanoma (PRAME) in Gynecological Tumors: A Single-institution Retrospective Analysis},
journal = {Anticancer Research},
year = {2024},
doi = {10.21873/anticanres.17377}
}
EUVIMED